GERN vs VRTX
GERN: First-in-class telomerase inhibitor company with FDA-approved RYTELO for myelodysplastic syndromes, now expanding into myelofibrosis with Phase 3 clinical data pending. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | GERN | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.41 | $472.57 | |
| Market cap as of 2026-07-23 | $917M | $121.4B | |
| P/E as of 2026-07-23 | n/a | 27.98 | |
| PEG as of 2026-07-23 | n/a | 2.31 | |
| Net margin as of 2026-07-23 | -34.3% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-23 | +97.3% | +86.2% | GERN higher |
| Operating margin as of 2026-07-23 | -26.4% | +38.3% | VRTX higher |
| ROE as of 2026-07-23 | -28.0% | +23.9% | VRTX higher |
| ROA as of 2026-07-23 | -12.1% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-23 | 1.09 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-07-23 | +68.6% | +10.1% | GERN higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | +10.4% | VRTX higher |
| Beta as of 2026-07-23 | 0.58 | 0.30 | |
| 1-year return as of 2026-07-22 close | +17.1% | +0.5% | GERN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.